Clinical Scenario: Treating Late-Line Relapsed Multiple Myeloma

News
Video

Following the repeat diagnostic workup presentation, an expert will lead the discussion, inviting the panel's input on the most appropriate treatment course for this patient.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
Photo of a woman with dark curly hair wearing a floral shirt
Image of a woman with gray hair on a light blue background
Photo of a woman with a blue border around the image
Image of a woman with dark hair wearing a floral shirt in front of a blurred background
Screenshot of Kiah Purcell, MSN, AGPCNP-BC, in a video call with the frame surrounded by an Oncology Nursing News branded border
Related Content
Line illustration of blood cells on a blue background

Teclistamab Safe, Effective for Older Adults With Multiple Myeloma

Roman Fabbricatore
May 26th 2025
Article

CRS and ICANS rates were similar in adults 75 years or older vs younger individuals with relapsed/refractory multiple myeloma.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

PDF of Rx Road Map for subcutaneous daratumumab in multiple myeloma

Rx Road Map: Subcutaneous Daratumumab in Multiple Myeloma

Sylwia Zielinska, RN
Published: May 7th 2025 | Updated: June 5th 2025
Article

A registered nurse gives best practices for use of subcutaneous daratumumab in multiple myeloma.

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape

Lindsay Fischer
April 13th 2023
Podcast

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

Image of red blood cells

Cilta-Cel Improves QOL, Extends Treatment Breaks vs SOC in R/R Myeloma

Ashling Wahner
April 22nd 2025
Article
Image of red blood cells

Daratumumab Decreased Progression Risk in High-Risk Smoldering MM

Jax DiEugenio
April 19th 2025
Article

Daratumumab showed a decrease in disease progression or death risk vs active monitoring in patients with high-risk smoldering multiple myeloma.